Prevention of Hepatocellular Carcinoma: Potential Targets, Experimental Models, and Clinical Challenges

Author(s): Yujin Hoshida, Bryan C. Fuchs, Kenneth K. Tanabe

Journal Name: Current Cancer Drug Targets

Volume 12 , Issue 9 , 2012

Become EABM
Become Reviewer


Chronic fibrotic liver diseases such as viral hepatitis eventually develop liver cirrhosis, which causes occurrence of hepatocellular carcinoma (HCC). Given the limited therapeutic efficacy in advanced HCC, prevention of HCC development could be an effective strategy for improving patient prognosis. However, there is still no established therapy to meet the goal. Studies have elucidated a wide variety of molecular mechanisms and signaling pathways involved in HCC development. Genetically-engineered or chemically-treated experimental models of cirrhosis and HCC have been developed and shown their potential value in investigating molecular therapeutic targets and diagnostic biomarkers for HCC prevention. In this review, we overview potential targets of prevention and currently available experimental models, and discuss strategies to translate the findings into clinical practice.

Keywords: Animal model, chemoprevention, clinical trial, hepatocellular carcinoma, liver cirrhosis, prevention, bile duct ligation, carbon tetrachloride, connective tissue growth factor, direct acting antiviral, diethylnitrosamine, dimethylnitrosamine, extracellular matrix, epidermal growth factor, genetic hemochromatosis

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2012
Published on: 14 November, 2012
Page: [1129 - 1159]
Pages: 31
DOI: 10.2174/15680096112091129
Price: $65

Article Metrics

PDF: 9